论文部分内容阅读
宿主免疫应答是决定乙型肝炎病毒(hepatitis B virus,HBV)感染转归的重要因素。机体抗病毒免疫功能不足,尤其是HBV特异性T细胞功能缺陷是造成HBV感染慢性化的主要原因。现有抗病毒药物虽可有效抑制病毒复制、减轻肝脏损伤和延缓疾病进展,但由于无法恢复患者机体抗病毒免疫功能,因而无法彻底治愈HBV感染。根据疾病发展的不同阶段,采用有效的抗病毒药物抑制病毒复制、HBV抗原抑制剂降低或清除表面抗原和HBeAg、HBV cccDNA抑制剂减少或控制病毒储存库,同时联合新的生物治疗策略恢复机体HBV特异性免疫功能,可能是彻底治愈慢性乙肝的有效途径。
Host immune response is an important factor in determining the outcome of hepatitis B virus (HBV) infection. Anti-virus immune function of the body, especially HBV-specific T cell dysfunction is the main cause of chronic HBV infection. Although the existing antiviral drugs can effectively inhibit virus replication, reduce liver damage and delay disease progression, HBV infection can not be completely cured due to the inability to recover the patient’s anti-viral immune function. According to different stages of disease development, the use of effective antiviral drugs to inhibit viral replication, HBV antigen inhibitors reduce or eliminate surface antigen and HBeAg, HBV cccDNA inhibitors reduce or control the virus repository, combined with new biological treatment strategies to restore the body of HBV Specific immune function may be an effective way to completely cure chronic hepatitis B.